| Business Summary | | Hyal
Pharmaceutical
Corp.
is
a
drug
delivery
company
engaged
in
research
and
development,
and
seeks
worldwide
commercialization
of
pharmaceutical
formulations
utilizing
its
proprietary
Hyaluronan
Induced
Targeting
and
Hyaluronan
Improved
Liposome
technologies
as
vehicles
for
drug
delivery.
The
Company
seeks
to
license
its
product
candidates
and
technologies
to
pharmaceutical
and
other
healthcare
companies
that
are
granted
the
right
to
manufacture,
market,
sell
or
sublicense
to
hospitals,
physicians,
consumers
and
companies.
The
Company's
Solarase
is
a
topical
gel
formulation
of
HA
and
the
non-steroidal
anti-inflammatory
drug
diclofenac,
and
is
being
developed
primarily
as
a
product
for
the
treatment
of
actinic
keratosis,
a
lesion
of
the
skin
that
may
precede
skin
cancer.
Compared
to
other
actinic
keratosis
treatments,
Solarase
is
non-invasive,
non-scarring
and
is
well
tolerated
by
patients.
The
Company's
other
products
under
development
are
Oralease,
Cardi-Clear,
HyClinda,
and
Cyclops. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cade
Struktur
Corporation
is
engaged
in
research
and
development
and
worldwide
commercialization
of
pharmaceutical
formulations
utilizing
its
proprietary
drug
delivery
technologies
HIT
and
HILT.
For
the
three
months
ended
3/31/01,
revenues
totaled
C$582
thousand,
up
from
$19
thousand.
Net
income
totaled
C$186
thousand
vs.
a
loss
of
$112
thousand.
Revenues
reflect
the
inclusion
of
royalty
income.
Net
income
also
reflects
the
absence
of
receiver's
fees. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1998 Pay | |
| Zenas Noon, Jr., Ph.D. Chairman,
Pres and CEO | $240K | Marc Cohen, M.D. Sr.
VP and CMO | 355K | Michael Byrne VP
- Fin. and Sec. | 153K | Eva Turley, Ph.D. VP
- Basic Research | 100K | Dollar amounts are as of 31-Dec-1998 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|